The Food and Drug Administration (FDA) has extended the review period for Orca-T in the treatment of patients with hematologic malignancies.
The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...
Orca Bio announced that the FDA has extended the review timeline of its BLA for Orca-T for the treatment of patients with hematologic malignancies.
Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe chronic graft versus host disease (GvHD). The Phase III ...
The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to July 6. The review extension comes after the company submitted additional data ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The treatment is designed to be ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medical biotechnology company ...
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results